🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New review article from NIHOxCam Oxford DPhil (=PhD) student now MRC WIMM Zoë Wong, Laura Dillon, PhD, FACMG, and I. Special issue editor: Mike Grunwald Levine Cancer. Zoë also has 1st au lab paper from yr1 @TheBethesdaLabs coming, + more 2 come w/ Beth Psaila authors.elsevier.com/a/1h0Up5P-YiG5…

What a great year Pranay Hegde a medical student from Cleveland Clinic had at @TheBethesdaLabs NIH Clinical Center as a NIH #MRSP Scholar. His important work on FLT3-TKD MRD before bone-marrow transplant coming soon to a conference and journal near you! NIH CC MedEd #HouriganLabAlumni

Excited to share our paper in Journal of Clinical Oncology: allogeneic HCT should be considered as a curative treatment for all patients with high-risk MDS, even for those with TP53 mutations. Thanks to all collaborators @ColemanLindsley Corey Cutler Chris Hourigan BMT CTN ascopubs.org/doi/10.1200/JC…

Persistent FLT3-ITD or NPM1 variants in pretransplant blood samples from patients with AML in their first remission were associated with “increased relapse and worse survival,” according to a study by Laura Dillon, PhD, FACMG of @thebethesdalabs and colleagues. 📚buff.ly/3EMOEJx

The best and the brightest from medical, dental, and vet schools around the US come to NIH for a year during training to do research. They work hard and do well by doing good. Was an honor to host Pranay Hegde - no surprise to see him win this national award for his work with us

Proud of Gege Gui & Pranay Hegde for their ASH abstract awards for work on the next stages of #PreMEASURE AML MRD project. Part 1 showed persistent FLT3-ITD +/or NPM1mut in CR1 blood before alloHCT assoc with ⬆relapse & death. What about FLT3-TKD, IDH1m, and IDH2m?

So proud of our HouriganLab #ASH23 superstar abstract award winners - biostats PhD student ⁦Gege Gui⁩ (oral on IDH2 MRD tomorrow Sun in sess617 at 9.30am and poster on IDH1 MRD on Mon) and medical student ⁦⁦Pranay Hegde⁩ presenting TKD MRD poster tomorrow (Sun).

Come listen (and support) Gege as she gives her first talk at an international hematology meeting! If we are serious about making things better for patients with blood cancer we need to encourage best and brightest students from other disciplines to work on our hardest problems

She crushed it! First major international talk for ⁦Gege Gui⁩ - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. ⁦@TheBethesdaLabs⁩ ⁦CIBMTR⁩ ⁦ASH⁩

Cleveland clinic medical student ⁦Cleveland Clinic⁩ ⁦Pranay Hegde⁩ presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at ⁦@TheBethesdaLabs⁩ ⁦NIH⁩ ⁦CIBMTR⁩

I encourage you to listen to the recorded poster presentation by Laura Dillon, PhD, FACMG (who is unable to attend ASH in person this year - due to another project she is working on)

Bottom lines: There does appear to be an association between level of FLT3-ITD persistence and clinical outcome (first time this has been definitively shown for AML MRD as far as I know). Levis and colleagues have found the same thing (they have an oral presentation later today)

Secondary primary malignancies are increasingly recognized as a risk of cellular therapies (esp. MDS/AML, also after chemotx/radiotx) - we were asked to bring up a ultra-deep NGS assay for DISCOVERY of TP53 mutations for screening prior to treatment medrxiv.org/content/10.110…

#ESHAL2024 Jordi Esteve chairs a very entertaining - and not entirely serious - debate discussing whether AML MRD conversion before alloSCT has to be achieved. Chris Hourigan is PRO; Charlie Craddock CBE is CON: Stay tuned, debate soon available on #ESHELEARNING #ESHCONFERENCES

news.vt.edu/content/news_v…

Excellent new paper in JAMA Oncology by Laura Dillon, PhD, FACMG Chris Hourigan et al on FLT3-ITD MRD prior to allo-HCT in AML! The amount of MRD matters! jamanetwork.com/journals/jamao…

TP53 mutation screening for patients at risk of myeloid malignancy | Leukemia ⁦Devdeep Mukhopadhyay⁩ ⁦⁦⁦Laura Dillon, PhD, FACMG⁩ nature.com/articles/s4137…

New Year, new job, a fresh start. After almost 8 years of service at the NIH I am excited to be starting this year off joining Chris Hourigan at the Virginia Tech Fralin Biomedical Research Institute Cancer Research Center in Washington, DC. Exciting things to come.

Delighted to have Dr. Dillon join us at the Virginia Tech Fralin Biomedical Research Institute Cancer Research Center in DC as Research Associate Professor. The Pre-MEASURE team is back together(!) as we, with help from others, dive into the MEASURE protocol and continue our Foundation for the National Institutes of Health work on AML MRD

#Tandem25 I'll be talking today (10.30am Ballroom B, 4th flr) about the Pre-MEASURE AML MRD project which used CIBMTR Clinical Data and Biospecimens. The current issue of nature.com/BMT focuses on this research, and is dedicated to Dr. Kristin Page our CIBMTR colleague